2 weeks Ago By ABMN Staff
Marathon Capital Management cut its position in shares of AstraZeneca PLC ( NASDAQ:AZN – Free Report ) by 0.1% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 161,872 shares of the company’s stock after selling 215 shares during the period.
AstraZeneca comprises about 3.2% of Marathon Capital Management’s investment portfolio, making the stock its 2nd largest position. Marathon Capital Management’s holdings in AstraZeneca were worth $12,624,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also modified their holdings of the company. Cox Capital Mgt LLC bought a new stake in shares of AstraZeneca during the first quarter worth $2,683,000. TD Asset Management Inc grew its holdings in shares of AstraZeneca by 8.
6% during the first quarter. TD Asset Management Inc now owns 1,537,410 shares of the company’s stock worth $104,160,000 after purchasing an additional 121,876 shares during the last quarter. Northcape Wealth Management LLC bought a new stake in shares of AstraZeneca during the second quarter worth $269,000.
Wealthcare Advisory Partners LLC grew its holdings in shares of AstraZeneca by 9.7% during the first quarter. Wealthcare Advisory Partners LLC now owns 6,136 shares of the company’s stock worth $416,000 after purchasing an additional 543 shares during the last quarter.
Finally, Cetera Advisors LLC grew its holdings in shares of AstraZeneca by 124.5% during the first quarter. Cetera Advisors LLC now owns 98,262 shares of the company’s stock worth $6,657,000 after purchasing an additional 54,488 shares during the last quarter.
20.35% of the stock is currently owned by institutional investors. Wall Street Analysts Forecast Growth Several brokerages have recently commented on AZN.
The Goldman Sachs Group started coverage on AstraZeneca in a report on Thursday, May 30th. They set a “buy” rating and a $97.00 target price on the stock.
Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Citigroup upgraded AstraZeneca to a “strong-buy” rating in a report on Monday, June 24th. Deutsche Bank Aktiengesellschaft cut AstraZeneca from a “hold” rating to a “sell” rating in a report on Friday, September 13th.
Finally, TD Cowen raised their price target on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th.
One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $89.
75. AstraZeneca Stock Up 0.8 % NASDAQ:AZN opened at $78.
18 on Friday. The firm has a market capitalization of $242.40 billion, a price-to-earnings ratio of 38.
32, a price-to-earnings-growth ratio of 1.45 and a beta of 0.47.
AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68.
The stock’s 50 day moving average price is $81.71 and its two-hundred day moving average price is $76.90.
The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.
69. AstraZeneca ( NASDAQ:AZN – Get Free Report ) last issued its earnings results on Thursday, July 25th. The company reported $0.
99 EPS for the quarter, topping the consensus estimate of $0.98 by $0.01.
AstraZeneca had a return on equity of 29.34% and a net margin of 13.11%.
The company had revenue of $12.45 billion during the quarter, compared to the consensus estimate of $12.62 billion.
During the same period in the previous year, the company posted $1.08 EPS. The firm’s revenue for the quarter was up 9.
1% compared to the same quarter last year. Equities research analysts expect that AstraZeneca PLC will post 4.05 earnings per share for the current fiscal year.
AstraZeneca Cuts Dividend The company also recently declared a Semi-Annual dividend, which was paid on Monday, September 9th. Investors of record on Friday, August 9th were paid a $0.49 dividend.
The ex-dividend date was Friday, August 9th. This represents a yield of 1.8%.
AstraZeneca’s dividend payout ratio (DPR) is presently 48.04%. AstraZeneca Profile ( Free Report ) AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Read More Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC ( NASDAQ:AZN – Free Report ).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter ..
